<DOC>
	<DOCNO>NCT02256111</DOCNO>
	<brief_summary>This study examine effect supervise exercise training cardiopulmonary function men receive combination enzalutamide ( ENZ ) androgen deprivation therapy ( ADT ) treatment non-metastatic , hormone-naïve prostate cancer . No study date examine efficacy , tolerability , safety exercise training prevent and/or mitigate common adverse toxicity men receive combination androgen suppression therapy hormone-naïve prostate cancer .</brief_summary>
	<brief_title>EXTEND Exercise Trial</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>1 . Male age ≥ 18 year . 2 . Histologicallyconfirmed adenocarcinoma prostate . 3 . Completion appropriate prior treatment local therapy ( i.e. , prostatectomy , radiation therapy equivalent ) , per NCCN Guidelines . 4 . Detectable PSA , define PSA ≥0.01 ng/ml 5 . Appropriate treatment ADT opinion treat physician . 6 . Serum total testosterone ≥150 ng/dL ( 5.2 nmol/L ) . 7 . ECOG performance status ≤ 1 ( Appendix A ) 8 . Planned treatment castration therapy ( GnRH agonist/antagonist ) ≥8 month . 9 . Must follow absolute contraindication cardiopulmonary exercise test and/or aerobic training determine attend oncologist : Absolute Contraindications Acute myocardial Infarction ( within 35 day plan study procedure ) Unstable angina Uncontrolled arrhythmia cause symptom hemodynamic compromise Recurrent syncope Active endocarditis Acute myocarditis pericarditis Symptomatic severe aortic stenosis Uncontrolled heart failure Acute ( within 3 month ) pulmonary embolus pulmonary infarction Thrombosis low extremity Suspected dissect aneurysm Uncontrolled asthma Pulmonary edema Room air desaturation rest &lt; 85 % Respiratory failure Acute noncardiopulmonary disorder may affect exercise performance aggravate exercise ( i.e . infection , renal failure , thyrotoxicosis ) Mental impairment lead inability cooperate . 10 . Able swallow enzalutamide comply study requirement . 11 . Must able complete acceptable cardiopulmonary exercise test ( CPET ) baseline ( see Section 9 ) , define least one following : Achieving plateau oxygen consumption concurrent increase power output ; Respiratory exchange ratio ≥ 1.1 ( RER ) ; Volitional exhaustion rating perceive exertion ≥ 17 ( RPE ) 12 . Must able complete acceptable onerepetition maximum ( 1RM ) strength assessment baseline ( see Section 9 ) , opinion fitness specialist , exercise physiologist , train designee administer test . 13 . Life expectancy ≥ 12 month . 14 . Must use condom sex pregnant woman . 15 . Male subject female partner childbearing potential must use 2 acceptable method birth control ( one must include condom barrier method contraception ) start screen continue throughout study period 3 month final study drug administration . Two acceptable method birth control thus include follow : Condom ( barrier method contraception ) ; AND One following require : Established use oral , injected implant hormonal method contraception female partner ; Placement intrauterine device ( IUD ) intrauterine system ( IUS ) female partner ; Additional barrier method : Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository female partner ; Tubal ligation female partner ; Vasectomy procedure result infertility ( e.g. , bilateral orchiectomy ) , 6 month 16 . Subjects must normal organ marrow function define : absolute neutrophil count &gt; 1,500/µL platelet &gt; 100,000/µL total bilirubin &lt; 2.5 X institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) &lt; 2.5 X institutional upper limit normal Creatinine ≤ 2.0 OR creatinine clearance &gt; 30 mL/min/1.73 m2 subject creatinine level institutional normal . 1 . Definite evidence metastatic prostate cancer , opinion treat physician . Pelvic retroperitoneal lymph node &lt; 2.0 cm short axis allow . 2 . Subjects treatment GnRH agonists/antagonists and/or antiandrogens within 1 year randomization . 3 . Use herbal product may hormonal antiprostate cancer activity and/or know decrease PSA value ( e.g. , saw palmetto ) systemic corticosteroid prostate cancer within 4 week day 29 visit ( start Enzalutamide ADT ) . 4 . Subjects radiotherapy within 12 week prior enter study recover adverse event due agent therapy administer treatment prostate cancer 4 week earlier . 5 . Subjects surgical procedure ( i.e . TURP , etc . ) within 4 week prior enter study . 6 . Subjects receive investigational agent . 7 . Significant cardiovascular disease , include : Symptomatic leave ventricular dysfunction know baseline leave ventricular ejection fraction ( LVEF ) multigated acquisition scan ( MUGA ) echocardiogram ( ECHO ) &lt; low limit institutional normal ( LLN ) . `` Symptomatic '' define New York Heart Association ( NYHA ) Class II great . Note : MUGA ECHCO NOT need measure establish eligibility study . Uncontrolled hypertension ( opinion treat provider ) . Myocardial infarction , severe angina , unstable angina within 6 month prior administration first dose study drug . History serious ventricular arrhythmia ( i.e. , ventricular tachycardia ventricular fibrillation ) within 12 month first dose study drug . Uncontrolled cardiac arrhythmia . Coronary peripheral artery bypass graft within 6 month first dose study drug . History CVA , TIA , rest claudication within 6 month first dose study drug . 8 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement ( opinion treat provider ) . 9 . Subjects condition ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease ) impair ability swallow retain enzalutamide exclude . 10 . History another invasive cancer within 5 year randomization exception ( ) nonmelanoma skin cancer ( b ) American Joint Committee Cancer ( AJCC ) Stage 0 1 cancer remote probability recurrence , opinion treat physician , consultation principal investigator . 11 . Known suspected brain metastasis leptomeningeal disease . 12 . History seizure condition may predispose seizure ( e.g. , prior cortical stroke , significant brain trauma ) time past . Also , history loss consciousness transient ischemic attack within 12 month Day 1 visit .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>